Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
Heart failure (HF) is a major public health problem characterised by a high rate of hospitalisation and death. The risk is maximal for patients admitted with acute heart failure (AHF). New therapies with solid proof of mortality reduction in both groups of patients with reduced and preserved ejectio...
Main Author: | Nechita Alexandru Cristian |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2022-12-01
|
Series: | Romanian Journal of Cardiology |
Subjects: | |
Online Access: | https://doi.org/10.2478/rjc-2022-0035 |
Similar Items
-
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
by: Aleix Olivella, et al.
Published: (2024-04-01) -
Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
by: Carlos Escobar, et al.
Published: (2022-09-01) -
Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
by: Makiko Nakamura, et al.
Published: (2023-06-01) -
Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01) -
Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020
by: Nancy Herrera-Leaño, et al.
Published: (2024-01-01)